Exscientia acquired by Recursion Pharmaceuticals

Recursion Pharmaceuticals has entered into a definitive agreement to acquire Exscientia in an all-stock transaction. This strategic move aims to bring together two artificial intelligence-driven drug discovery specialists, creating a comprehensive platform that spans the entire process, from biology to computational chemistry. The deal is structured as a stock swap, where Recursion shareholders will hold the majority of the combined entity's capital, while Exscientia shareholders will receive a minority stake in the new company. The strategic rationale behind this merger is to combine complementary technological approaches, with Recursion focusing on large-scale biological analysis and Exscientia bringing advanced AI-driven molecular design expertise. The combined company will retain the Recursion name and benefit from a strengthened financial foundation, including significant cash reserves to support its operations for several years. The transaction is also expected to generate substantial synergies by leveraging shared technological platforms, data, and research capabilities, with the ambition of accelerating the discovery of new drug candidates and enhancing the overall efficiency of pharmaceutical development programs.